Skip to main content

Table 3 Treatment, complications and outcome

From: COVID-19 in adults with dementia: clinical features and risk factors of mortality—a clinical cohort study on 125 patients

  Total (n = 125) Survivors (n = 97) Non-survivors (n = 28) P
Covid severity*     0.001
 Mild 37.6% (47) 48.5% (47) 0.0% (0)  
 Moderate 27.2% (34) 35.0% (34) 0.0% (0)  
 Severe 35.2% (44) 16.5% (16) 100% (28)  
 Treatment
Oxygen therapy 60.0% (75) 50.5% (49) 92.9% (26) < 0.0001
Maximal flow (L/min) 3.0 (2.0–6.0) 3.0 (2.0–6.0) 5.0 (2.5–15.0) 0.018
Antibiotics use 61.6% (77) 57.7% (56) 75.0% (21) 0.074
Combination of antibiotics 33.6% (42) 29.9% (29) 46.4% (13) 0.082
Beta-lactamine 54.4% (68) 50.5% (49) 67.9% (19) 0.079
 Macrolides 37.6% (47) 35.1% (34) 46.4% (13) 0.279
2nd line antibiotics 17.6% (22) 14.4% (14) 28.6% (8) 0.096
 Steroids 8.0% (10) 8.2% (8) 7.1% (2) 1.000
Hydroxychloroquine 16.8% (21) 16.5% (16) 17.9% (5) 1.000
 Neuroleptics 4.8% (6) 5.2% (5) 3.6% (1) 0.678
Complications
 ARDS 25.6% (32) 6.2% (6) 92.9% (26) < 0.0001
Cardiac injury 13.6% (17) 9.3% (9) 28.6% (8) 0.024
 ACKI 16.8% (21) 12.4% (12) 32.1% (9) 0.021
Bacterial superinfection 14.4% (18) 11.3% (11) 25.0% (7) 0.122
Behavioural disorder 19.2% (24) 21.6% (21) 10.7% (3) 0.278
Diabetic ketoacidosis 2.4% (3) 3.1% (3) 0.0% (0) 1.000
 Seizure 2.4% (3) 2.1% (2) 3.6% (1) 0.536
 Stroke 2.4% (3) 2.1% (2) 3.6% (1) 1.000
 Outcome Total (n=125) Survivors (n=97) Non-survivors (n=28)  
Total mortality 22.4% (28)    
Delay admission-death    8.5 (3.7–16)
Length of stay   16 (11–19.7)   
Discharge home before end of follow-up 40.2% (39)   
  1. Data are median (IQI), % (n). P values > 0.05 (bold) indicates significant differences between survivors and non-survivors
  2. *COVID severity defined according to WHO guidelines
  3. ACKI acute kidney injury, ARDS acute respiratory distress syndrome